Benzinga | Oct 1, 2021 08:23AM EDT

CRISPR Therapeutics To Present Preclinical Data At Society For Immunotherapy Of Cancer (SITC) 36th Annual Meeting On Nov. 10

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, to be held both virtually and at the Walter E. Washington Convention Center in Washington, D.C., from November 10 to 14, 2021. The Company also announced an oral presentation at the SITC 2021 Pre-Conference Program, The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations, which will be held from 2:00 p.m. -- 6:00 p.m. ET on November 10, 2021.



CRISPR Therapeutics presentation:

Title: CRISPR/Cas9 gene-edited allogeneic CAR-T cells targeting CD33 show high preclinical efficacy against AML without long-term hematopoietic toxicity

Abstract Number and Type: 133, poster

Date and Time: Friday, November 12, 2021, 7:00 a.m. -- 8:30 p.m. ET

Location: Walter E. Washington Convention Center, Hall E, or https://www.sitcancer.org/2021/home

Presented jointly with Nkarta:

Title: A combined strategy of CD70 CAR co-expression with membrane-bound IL-15 and CISH knockout results in enhanced NK cytotoxicity and persistence

Abstract Number and Type: 16439, oral

Date and Time: Wednesday, November 10, 2021, 2:40 p.m. ET

Location: Walter E. Washington Convention Center, or https://www.sitcancer.org/2021/program/pre-conference-programs/industryprogram

Title: CISH gene-knockout anti-CD70-CAR NK cells demonstrate potent anti-tumor activity against solid tumor cell lines and provide partial resistance to tumor microenvironment inhibition

Abstract Number and Type: 113, poster

Date and Time: Friday, November 12, 2021, 7:00 a.m. -- 8:30 p.m. ET

Location: Walter E. Washington Convention Center, Hall E, or https://www.sitcancer.org/2021/home